---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-051567"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:50:08.509981+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Apimeds Pharmaceuticals appoints Erick J. Frim as CFO, replacing Mark Corrao

## Summary
- Erick J. Frim, 67, appointed CFO effective May 30, 2025, succeeding Mark Corrao.
- Mr. Frim has over 40 years of financial management experience, most recently as interim CFO of Helio Corporation.
- Compensation: $2,500 per month for first 8 hours, $250 per hour thereafter under a one-year consulting agreement.
- No familial relationships or reportable related-party transactions with the Company.

## SEC filing metadata
- accession: 0001213900-25-051567
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/ea024484201-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-051567
- JSON: https://secwatch.observer/filing/0001213900-25-051567.json
- Plain text: https://secwatch.observer/filing/0001213900-25-051567.txt

## Key facts
- Executive change
  Mark Corrao departed as Chief Financial Officer at Apimeds Pharmaceuticals US, Inc..
  - Action: replaced
  - Role: Chief Financial Officer
  source text: On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm
- Executive change
  Erick J. Frim was appointed as Chief Financial Officer at Apimeds Pharmaceuticals US, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.